Tags

Type your tag names separated by a space and hit enter

Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study.
J Hypertens 2006; 24(3):581-9JH

Abstract

BACKGROUND

Cardiovascular diseases are associated with disturbances in calcium metabolism, including increased urinary calcium, vitamin D insufficiency, and decreased bone mineral density. Antihypertensive drugs may increase the risk of falling. However, risk of fracture in patients treated with non-diuretic cardiovascular drugs is largely unknown.

AIM

We investigated associations between fracture risk and treatment with commonly used cardiovascular drugs: beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and calcium-channel blockers.

DESIGN

A population-based pharmaco-epidemiological case-control study with fracture in year 2000 as outcome and drug use during the previous 5 years as exposure. We used nationwide computerized registers to assess individual use of drugs and related these data to individual fracture records and information on socio-economic and health-related confounders.

RESULTS

We included 124,655 cases that sustained a fracture and 373,962 age and gender-matched controls. After adjustment for potential confounders, risk of any fracture was reduced by 9% [odds ratio (OR) 0.91; 95% confidence interval (CI), 0.88-0.93] in users of beta-blockers, by 6% (OR, 0.94; 95%CI, 0.91-0.96) in users of calcium-channel blockers, and by 7% (OR, 0.93; 95%CI, 0.90-0.96) in users of ACE inhibitors. Moreover, risk of hip fractures was reduced significantly by 7-14% in users of the three groups of drugs. No major differences were found between men and women or in subjects younger or older than 70 years of age. Sub-analyses indicated differences between groups of calcium-channel blockers, as use of non-dihydropyridine drugs was associated with a larger risk reduction than use of dihydropyridine drugs.

CONCLUSION

Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a small but significantly reduced risk of fracture.

Authors+Show Affiliations

Department of Endocrinology and Metabolism, Aarhus University Hospital, Aarhus Sygehus, Aarhus, Denmark. rejnmark@post6.tele.dkNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16467662

Citation

Rejnmark, Lars, et al. "Treatment With Beta-blockers, ACE Inhibitors, and Calcium-channel Blockers Is Associated With a Reduced Fracture Risk: a Nationwide Case-control Study." Journal of Hypertension, vol. 24, no. 3, 2006, pp. 581-9.
Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens. 2006;24(3):581-9.
Rejnmark, L., Vestergaard, P., & Mosekilde, L. (2006). Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. Journal of Hypertension, 24(3), pp. 581-9.
Rejnmark L, Vestergaard P, Mosekilde L. Treatment With Beta-blockers, ACE Inhibitors, and Calcium-channel Blockers Is Associated With a Reduced Fracture Risk: a Nationwide Case-control Study. J Hypertens. 2006;24(3):581-9. PubMed PMID: 16467662.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. AU - Rejnmark,Lars, AU - Vestergaard,Peter, AU - Mosekilde,Leif, PY - 2006/2/10/pubmed PY - 2006/5/5/medline PY - 2006/2/10/entrez SP - 581 EP - 9 JF - Journal of hypertension JO - J. Hypertens. VL - 24 IS - 3 N2 - BACKGROUND: Cardiovascular diseases are associated with disturbances in calcium metabolism, including increased urinary calcium, vitamin D insufficiency, and decreased bone mineral density. Antihypertensive drugs may increase the risk of falling. However, risk of fracture in patients treated with non-diuretic cardiovascular drugs is largely unknown. AIM: We investigated associations between fracture risk and treatment with commonly used cardiovascular drugs: beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and calcium-channel blockers. DESIGN: A population-based pharmaco-epidemiological case-control study with fracture in year 2000 as outcome and drug use during the previous 5 years as exposure. We used nationwide computerized registers to assess individual use of drugs and related these data to individual fracture records and information on socio-economic and health-related confounders. RESULTS: We included 124,655 cases that sustained a fracture and 373,962 age and gender-matched controls. After adjustment for potential confounders, risk of any fracture was reduced by 9% [odds ratio (OR) 0.91; 95% confidence interval (CI), 0.88-0.93] in users of beta-blockers, by 6% (OR, 0.94; 95%CI, 0.91-0.96) in users of calcium-channel blockers, and by 7% (OR, 0.93; 95%CI, 0.90-0.96) in users of ACE inhibitors. Moreover, risk of hip fractures was reduced significantly by 7-14% in users of the three groups of drugs. No major differences were found between men and women or in subjects younger or older than 70 years of age. Sub-analyses indicated differences between groups of calcium-channel blockers, as use of non-dihydropyridine drugs was associated with a larger risk reduction than use of dihydropyridine drugs. CONCLUSION: Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a small but significantly reduced risk of fracture. SN - 0263-6352 UR - https://www.unboundmedicine.com/medline/citation/16467662/Treatment_with_beta_blockers_ACE_inhibitors_and_calcium_channel_blockers_is_associated_with_a_reduced_fracture_risk:_a_nationwide_case_control_study_ L2 - http://Insights.ovid.com/pubmed?pmid=16467662 DB - PRIME DP - Unbound Medicine ER -